Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that the company and collaborators from leading ...
Researchers built an open tool to handle complex genome sequencing data, offering automated quality control, improved variant ...
Low-dose radiation as a preconditioning regimen for dendritic cell vaccines. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not include a full text component.
RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical translation of diagnostic RNA-seq has not been widely achieved. Researchers at ...
Caris received FDA approval in November 2024 for MI Cancer Seek, a tissue-based assay that is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing ...
The origin of many diseases begins at the cellular level and involves multiple molecular interactions. However, previous methods have struggled to accurately observe changes in individual cells.
We validated a clinical bait-capture WTS assay using 78 solid tumor samples across diverse tissue types, including 59 with known fusions or oncogenic splice variants. Sensitivity was assessed against ...
Precision oncology is shifting toward comprehensive transcriptome profiling to reveal fusions, splice variants, and expression changes that DNA panels miss. Yet obtaining reliable data from degraded ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results